Germany And France Preventively Suspend The Use Of The AstraZeneca Vaccine Due To Its Possible Relationship With The Formation Of Thrombi

Germany and France have preventedly suspended vaccination with the AstraZeneca formula against the coronavirus after the detection of several cases of thrombosis, the German Ministry of Health and the President of the French Republic, Emmanuel Macron, reported on Monday. The German Government thus follows the recommendation of the Paul Ehrlich Institute (PEI), competent in the matter, which considers that it is necessary to verify the potential relationship between this vaccine and the new cases of thrombosis registered in Europe after its inoculation.

In addition, the German Ministry of Health has pointed out that in any case it will be the European Medicines Agency (EMA) who ultimately decides “if this new information affects the authorization of the vaccine and in what way.”


Italy has also suspended vaccination with AstraZeneca in the country today as a precaution following recent cases of thrombosis in Europe, sources from the Italian Medicines Agency (AIFA) confirmed. The decision is made after the AIFA suspended the inoculation of a batch of this vaccine last week, after the death of a military man and a policeman in Sicily, which the Italian Justice is investigating.

The news comes after Denmark also suspended vaccination with AstraZeneca last week for possible thrombus effects. Italy temporarily withheld vaccination with a batch of AstraZeneca as a precaution, following clotting problems in other European countries. The Norwegian authorities also announced the suspension, but the European Medicines Agency said last Thursday that it saw no problems.

“There is no indication that vaccination has caused these conditions, which are not listed as side effects of this vaccine. The position of the EMA safety committee is that the benefits of the vaccine continue to outweigh its risks and the vaccine can continue to be administered as long as thromboembolic cases are being investigated. The EMA is already reviewing all cases and other conditions related to blood clots, reported after vaccination with the COVID-19 vaccine AstraZeneca, “stated the EMA.

“The number of thromboembolic cases in vaccinated people is not higher than that observed in the general population. As of March 10, 2021, 30 cases of thromboembolic events had been reported among about 5 million people vaccinated with the COVID-19 vaccine. AstraZeneca in the European Economic Area “, added the European agency.



Leave a Reply

Your email address will not be published.

82 + = 84